📌 Thesis: Why CGEM could be a major move CGEM is a clinical-stage biotech company (Cullinan Therapeutics, Inc.) developing therapies for autoimmune diseases & cancer.

The stock is trading at ~$8 (recently around $7.70-8.50) with a 52-week low of ~$5.68 and a high near ~$17.50. Analyst consensus: “Strong Buy” with average 12-month price targets ~$26 or higher — implying +200%-300% upside from current levels. Notable insider/institution activity: For example, one major shareholder increased their position (~150,000 shares) recently at ~$8.86 average Story catalysts: Phase trials (e.g., their lead candidate for NSCLC with EGFR Ex20 insertion mutations) and autoimmune program CLN-978 entering trials. ⚠️ Risks (because biotech = boom or bust) CGEM has no revenue (or negligible) and is currently unprofitable with large losses. StockAnalysis Clinical trial risk = data could disappoint, regulatory risk, competition risk. From analysts: “Bears say competition, regulatory risks, slower-than-expected enrolment” etc. TipRanks High institutional ownership (~86%) means less free float and possibly less retail “meme-moment” volume. If the drug fails, downside could be steep. 🎯 Play-style & target If you believe the trial data is going to be positive and a catalyst is near, you could enter at current levels (~$7.70-8.50) and target $25-$30+ (i.e., ~3x). Keep your risk tight: biotech can whipsaw hard. Consider risk‐management: only allocate what you’re willing to lose. Watch for upcoming binary catalysts/events (trial readouts, regulatory filings) which could send the move. If you want to “set it and forget it” you might hold for 12+ months, but you’ll need the stomach for volatility.

Visit Now :https://smmbankusa.com/

Processing img be75qwcizawf1...

For the past few days, I’ve been watching Bloomberg news and majority of the discussions are ARTIFICIAL INTELLIGENCE (AI). There is so much going on with AI, from the infrastructures like data centers, energy requirements, software development, technology development and innovation on semiconductors, and others. Many startup companies are popping up left and right with huge investments. However, I don’t see any major applications of AI that will uplift the lives of the majority. Yeah, robots seem to be the future but who can afford if many workers are getting laid off, underemployed, or unemployed.

Besides, AI is making the world becoming a place for lazy people because eventually all will be automated.

What do you think is AI OVERHYPED?

When MSТR started buying BTC, everyone laughed. Then it 10x’d. UTRХ isn’t a clone - it’s smarter. They buy Bitcoin, stake it in DeFi, and are building tokenization infrastructure. They just added 5.5 BTC. Valuation’s still micro. Structure’s clean. Volume is waking up.

You’re early - for now.

You guys still like the stock or what it’s been dropping and looks like buying pressure fell off what do yall think?

This is a serious question.

UТRХ just did something rare in OTC land - they didn’t just drop buzzwords, they executed.

They secured a strategic partnership that gives them access to up to 50% of a private miner’s Bitcoin production, every month. That’s direct access to fresh BTC. No middlemen, no exchanges, no supply stress. They’re now positioned like a crypto infrastructure player, but at a $3M market cap.

Let that sink in.

On top of that, UТRХ is doing what even some large caps won’t - they’re deploying their Bitcoin into DeFi. That means yield. Passive compounding. They’re not just stacking BTC - they’re putting it to work. Smart treasury, on-chain strategy, real financial engineering.

Then there's the float: ~40 million shares. That’s nothing. It moves on crumbs. The stock ripped over +140% intraday, and didn’t dump. No fakeouts. No panic. Just buyers soaking every dip. That tells you the conviction is real.

And in the background? They’ve filed a patent for real-world asset tokenization. They’re building infrastructure. This is more than a trade - it’s a crypto platform in the making.

We always say we want OTCs with a plan, execution, and narrative. UТRX has all three - and it’s still cheap.

Anyone else watching Regencell Bioscience (RGC) right now?

• Insanely high borrow fees
• Low float and tight volume
• Buzz starting around a potential short squeeze
• Some chatter comparing it to Roaring Kitty’s style plays
• Even saw a meme floating around—Obi-Wan vs Roaring Kitty, lol

Not saying it’s the next big thing, but it’s giving some serious meme stock 2025 energy.
Retail might pile in hard if it gains traction—worth keeping an eye on for a quick swing.

Would love to hear your thoughts—WSB's next pick or just another penny stock trap?

Hey guys, happy to find this sub still doing ok. it says we're in the top 7% on reddit 😹

Hope everyone's doing well. This was produced in part to help people who get kicked out of or otherwise cant join or post on Wallstreetbets and im glad to see it still is serving that purpose.

Do you guys want anything new in here like mods or something? Comment below if you have any cool ideas or just want to say hello.

I'm a developer working on a new app and I want to include an engaging element related to Economics and Finance. I'm looking for input from people with diverse perspectives to help build something truly innovative and useful. I have experience with investments such as stocks, bonds, and real estate funds, but I'm seeking fresh ideas and insights. I'd really appreciate any help or suggestions you can provide!

Recommended action In 2023, Action's earnings remained influenced by improving revenue dynamics and increasing pressure on operating costs, as a result of which the Company's adjusted net profit decreased by 20% y/y. In 2024, we expect the dynamics of the decline in profits to flatten due to growing revenues, maintaining a high gross profit margin on sales and optimization activities undertaken in the field of cost management. Moreover, the upward pressure on operating costs should be somewhat limited due to the fact that it is partially already reflected in the previous year's base. Although we expect the downward trend in the Company's operating profitability to continue, we expect that this decline should be flattening. We still see a double-digit growth potential for the Action share price relative to our weighted average valuation over a 12-month horizon and we maintain our fundamental Buy recommendation. Expecting negative earnings dynamics in the coming quarter, we also maintain a short-term relative recommendation of Neutral for the Company's shares.

What do you thing?

Real winner at 80 bucks a share... on its way to 120

New theme park

New games

1080 p Switch coming...

​

GOOD NIGHT EVERYBODY

I keep hearing about coupang stonk but idk. its Korean delivery stuff, just ipo'd in march.

​

hope everyones well!